Recanalization therapies in Acute ischemic stroke patients impact of prior treatment with novel oral anticoagulants on bleeding complications and outcome a pilot study

Circulation

Volumn 132, Issue 13, 2015, Pages 1261-1269

  Seiffge, David J ^a   Hooff, Robbert Janvan ^b   Nolte, Christian H ^c   Béjot, Yannick ^d   Turc, Guillaume ^e   Ikenberg, Benno ^f   Berge, Eivind ^g   Persike, Malte ^h   Dequatre Ponchelle, Nelly ⁱ   Strbian, Daniel ^j   Pfeilschifter, Waltraud ^k   Zini, Andrea ^l   Tveiten, Arnstein ^m   Næss, Halvor ⁿ   Michel, Patrik ^o   Sztajzel, Roman ^p   Luft, Andreas ^q   Gensicke, Henrik ^a   Traenka, Christopher ^a   Hert, Lisa ^a   Scheitz, Jan F ^c   De Marchis, Gian Marco ^a   Bonati, Leo H ^a   Peters, Nils ^a   Charidimou, Andreas ^r   Werring, David J ^r   Palm, Frederick ^s   Reinhard, Matthias ^t   Niesen, Wolf Dirk ^t   Nagao, Takehiko ^u   Pezzini, Alessandro ^v   Caso, Valeria ^m   Nederkoorn, Paul J ^w   Kägi, Georg ^x   Von Hessling, Alexander ^a   Padjen, Visnja ^y   Cordonnier, Charlotte ⁱ   Erdur, Hebun ^c   Lyrer, Philippe A ^a   Brouns, Raf ^b   Steiner, Thorsten ^f,z   Tatlisumak, Turgut ^j,aa,ab   Engelter, Stefan T ^a,ac   more..

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d DIJON UNIVERSITY HOSPITAL   (France)

^e CENTRE HOSPITALIER SAINTE ANNE   (France)

^f Frankfurt Höchst City Hospital   (Germany)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

^h JOHANNES GUTENBERG UNIVERSITY   (Germany)

ⁱ LILLE UNIVERSITY HOSPITAL   (France)

^j HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^k UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^l AUSL Modena   (Italy)

^m University Hospital Lausanne ^*  (Italy)

ⁿ HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^o LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^p GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^q UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^r NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^s Municipal Hospital   (Germany)

^t UNIVERSITY OF FREIBURG   (Germany)

^u TOKYO WOMEN S MEDICAL UNIVERSITY MEDICAL CENTER EAST   (Japan)

^v UNIVERSITY OF BRESCIA   (Italy)

^w UNIVERSITY OF AMSTERDAM   (Netherlands)

^x CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^y Clinical Centre of Serbia   (Serbia)

^z UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^aa UNIVERSITY OF GOTHENBURG   (Sweden)

^ab SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^ac Felix Platter Spital   (Switzerland)

more..

Author keywords

Anticoagulants; Endovascular procedures; Intra arterial treatment; Intracranial hemorrhages; Ischemic stroke; Non Vitamin K antagonist oral anticoagulants; Thrombolytic therapy; Vitamin K antagonists

Indexed keywords

ACENOCOUMAROL; APIXABAN; DABIGATRAN; PHENPROCOUMON; RIVAROXABAN; ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; FIBRINOLYTIC AGENT; VITAMIN K GROUP;

AGED; ARTICLE; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; COMPARATIVE STUDY; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT SAFETY; PILOT STUDY; PRIORITY JOURNAL; ACUTE DISEASE; ANTAGONISTS AND INHIBITORS; BLOOD; CEREBRAL HEMORRHAGE; CHEMICALLY INDUCED; CLASSIFICATION; CLINICAL TRIAL; COHORT ANALYSIS; COMPLICATION; INCIDENCE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME; VERY ELDERLY; ADULT; ANTICOAGULANT THERAPY; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; DRUG SAFETY; EUROPEAN COOPERATIVE ACUTE STROKE STUDY II; FOLLOW UP; MAGNETIC RESONANCE ANGIOGRAPHY; NATIONAL HEALTH ORGANIZATION; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROLOGIC DISEASE ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; RANKIN SCALE; RECANALIZATION; THROMBOCYTE COUNT;

ACUTE DISEASE; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; COHORT STUDIES; FACTOR XA INHIBITORS; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PILOT PROJECTS; THROMBOLYTIC THERAPY; TREATMENT OUTCOME; VITAMIN K;

EID: 84946226898     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.115.015484     Document Type: Article

References (51)

1. Lip GY, Brechin CM, Lane DA. The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest. 2012;142:1489-1498. doi: 10.1378/chest.11-2888.
2. Alberts MJ, Eikelboom JW, Hankey GJ. Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation. Lancet Neurol. 2012;11:1066-1081. doi: 10.1016/S1474-4422 (12) 70258-2.
3. Ntaios G, Papavasileiou V, Diener HC, Makaritsis K, Michel P. Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials. Stroke. 2012;43:3298-3304. doi: 10.1161/STROKEAHA.112.673558.
4. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a metaanalysis of randomised trials. Lancet. 2014;383:955-962. doi: 10.1016/S0140-6736 (13) 62343-0.
5. Weitz JI. New oral anticoagulants: a view from the laboratory. Am J Hematol. 2012;87(suppl 1):S133-S136. doi: 10.1002/ajh.23139.
6. Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med. 2011;62:41-57. doi: 10.1146/annurev-med-062209-095159.
7. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan PW Jr, Qureshi AI, Rosenfield K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44:870-947. doi: 10.1161/STR.0b013e318284056a.
8. Mazya MV, Lees KR, Markus R, Roine RO, Seet RC, Wahlgren N, Ahmed N; Safe Implementation of Thrombolysis in Stroke Investigators. Safety of intravenous thrombolysis for ischemic stroke in patients treated with warfarin. Ann Neurol. 2013;74:266-274. doi: 10.1002/ana.23924.
9. Xian Y, Liang L, Smith EE, Schwamm LH, Reeves MJ, Olson DM, Hernandez AF, Fonarow GC, Peterson ED. Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. JAMA. 2012;307:2600-2608. doi: 10.1001/jama.2012.6756.
10. Brouns R, Van Hooff RJ, De Smedt A, Moens M, De Raedt S, Uyttenboogaart M, Luijckx GJ, Jochmans K, De Keyser J. Acute stroke management in patients taking dabigatran. CNS Neurosci Ther. 2012;18:616-622. doi: 10.1111/j.1755-5949.2012.00329.x.
11. Steiner T, Böhm M, Dichgans M, Diener HC, Ell C, Endres M, Epple C, Grond M, Laufs U, Nickenig G, Riess H, Röther J, Schellinger PD, Spannagl M, Veltkamp R. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol. 2013;102:399-412. doi: 10.1007/s00392-013-0560-7.
12. Diener HC, Foerch C, Riess H, Röther J, Schroth G, Weber R. Treatment of acute ischaemic stroke with thrombolysis or thrombectomy in patients receiving anti-thrombotic treatment. Lancet Neurol. 2013;12:677-688. doi: 10.1016/S1474-4422 (13) 70101-7.
13. Hankey GJ, Norrving B, Hacke W, Steiner T. Management of acute stroke in patients taking novel oral anticoagulants. Int J Stroke. 2014;9:627-632. doi: 10.1111/ijs.12295.
14. Lee VH, Conners JJ, Prabhakaran S. Intravenous thrombolysis in a stroke patient taking dabigatran. J Stroke. Cerebrovasc Dis. 2012;21:916.e11-916.e12. doi: 10.1016/j.jstrokecerebrovasdis.2012.04.008.
15. Sangha N, El Khoury R, Misra V, Lopez G. Acute ischemic stroke treated with intravenous tissue plasminogen activator in a patient taking dabigatran with radiographic evidence of recanalization. J Stroke Cerebrovasc Dis. 2012;21:917.e5-917.e8. doi: 10.1016/j.jstrokecerebrovasdis.2012.05.003.
16. Testai FD. Intravenous thrombolysis in a stroke patient taking dabigatran. J Stroke. Cerebrovasc Dis. 2013;22:894. doi: 10.1016/j. jstrokecerebrovasdis.2012.06.017.
17. De Smedt A, De Raedt S, Nieboer K, De Keyser J, Brouns R. Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran. Cerebrovasc Dis. 2010;30:533-534. doi: 10.1159/000319886.
18. Pfeilschifter W, Abruscato M, Hövelmann S, Baas H. Thrombolysis in a stroke patient on dabigatran anticoagulation: case report and synopsis of published cases. Case Rep Neurol. 2013;5:56-61. doi: 10.1159/000350570.
19. Fluri F, Heinen F, Kleinschnitz C. Intravenous thrombolysis in a stroke patient receiving rivaroxaban. Cerebrovasc Dis Extra. 2013;3:153-155. doi: 10.1159/000355839.
20. Kawiorski MM, Alonso-Canovas A, De Felipe Mimbrera A, Sainz De La Maza S, Alvarez-Velasco R, Zarza B, Masjuan J. Successful intravenous thrombolysis in acute ischaemic stroke in a patient on rivaroxaban treatment. Thromb Haemost. 2014;111:557-558. doi: 10.1160/TH13-06-0472.
21. Seiffge DJ, Traenka C, Gensicke H, Tsakiris DA, Bonati LH, Peters N, Lyrer P, Engelter ST. Intravenous thrombolysis in stroke patients receiving rivaroxaban. Eur J Neurol. 2014;21:e3-e4. doi: 10.1111/ene.12285
22. Van Hooff RJ, Nieboer K, De Smedt A, Yperzeele L, Jochmans K, De Keyser J, Brouns R. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke in a patient treated with rivaroxaban. Clin Neurol Neurosurg. 2014;122:133-134. doi: 10.1016/j. clineuro.2013.12.029.
23. De Smedt A, Cambron M, Nieboer K, Moens M, Van Hooff RJ, Yperzeele L, Jochmans K, De Keyser J, Brouns R. Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with apixaban. Int J Stroke. 2014;9:E31. doi: 10.1111/ijs.12315.
24. Müller P, Topakian R, Sonnberger M, Nußbaumer K, Windpessl M, Eder V, Nesser HJ, Trenkler J, Haring HP. Endovascular thrombectomy for acute ischemic stroke patients anticoagulated with dabigatran. Clin Neurol Neurosurg. 2013;115:2257-2259. doi: 10.1016/j.clineuro.2013.07.017.
25. Casado Naranjo I, Portilla-Cuenca JC, Jiménez Caballero PE, Calle Escobar ML, Romero Sevilla RM. Fatal intracerebral hemorrhage associated with administration of recombinant tissue plasminogen activator in a stroke patient on treatment with dabigatran. Cerebrovasc Dis. 2011;32:614-615. doi: 10.1159/000334578.
26. Kern R, Nagayama M, Toyoda K, Steiner T, Hennerici MG, Shinohara Y. Comparison of the European and Japanese guidelines for the management of ischemic stroke. Cerebrovasc Dis. 2013;35:402-418. doi: 10.1159/000351753.
27. Gensicke H, Zinkstok SM, Roos YB, Seiffge DJ, Ringleb P, Artto V, Putaala J, Haapaniemi E, Leys D, Bordet R, Michel P, Odier C, Berrouschot J, Arnold M, Heldner MR, Zini A, Bigliardi G, Padjen V, Peters N, Pezzini A, Schindler C, Sarikaya H, Bonati LH, Tatlisumak T, Lyrer PA, Nederkoorn PJ, Engelter ST. IV thrombolysis and renal function. Neurology. 2013;81:1780-1788. doi: 10.1212/01.wnl.0000435550.83200.9e.
28. Scheitz JF, Seiffge DJ, Tütüncü S, Gensicke H, Audebert HJ, Bonati LH, Fiebach JB, Tränka C, Lyrer PA, Endres M, Engelter ST, Nolte CH. Doserelated effects of statins on symptomatic intracerebral hemorrhage and outcome after thrombolysis for ischemic stroke. Stroke. 2014;45:509-514. doi: 10.1161/STROKEAHA.113.002751.
29. Zinkstok SM, Engelter ST, Gensicke H, Lyrer PA, Ringleb PA, Artto V, Putaala J, Haapaniemi E, Tatlisumak T, Chen Y, Leys D, Sarikaya H, Michel P, Odier C, Berrouschot J, Arnold M, Heldner MR, Zini A, Fioravanti V, Padjen V, Beslac-Bumbasirevic L, Pezzini A, Roos YB, Nederkoorn PJ. Safety of thrombolysis in stroke mimics: results from a multicenter cohort study. Stroke. 2013;44:1080-1084. doi: 10.1161/STROKEAHA.111.000126.
30. Engelter ST, Soinne L, Ringleb P, Sarikaya H, Bordet R, Berrouschot J, Odier C, Arnold M, Ford GA, Pezzini A, Zini A, Rantanen K, Rocco A, Bonati LH, Kellert L, Strbian D, Stoll A, Meier N, Michel P, Baumgartner RW, Leys D, Tatlisumak T, Lyrer PA. IV thrombolysis and statins. Neurology. 2011;77:888-895. doi: 10.1212/WNL.0b013e31822c9135.
31. Hacke W, Kaste M, Fieschi C, Von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352:1245-1251.
32. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333:1581-1587.
33. Brown DL, Johnston KC, Wagner DP, Haley EC Jr. Predicting major neurological improvement with intravenous recombinant tissue plasminogen activator treatment of stroke. Stroke. 2004;35:147-150. doi: 10.1161/01. STR.0000105396.93273.72.
34. Efron B. Bootstrap methods: Another look at the jackknife. Ann Stat. 1979;7:1-26.
35. Stuart EA. Matching methods for causal inference: a review and a look forward. Stat Sci. 2010;25:1-21. doi: 10.1214/09-STS313.
36. Rubin DB: Multiple Imputations for Nonresponse in Surveys. New York: Wiley & Sons; 1987.
37. Bryer JM. Trimatch: an R package for propensity score matching of nonbinary treatments. 2014. http://www.edii.uclm.es/~useR-2013/abstracts/files/122-Bryer-TriMatch.pdf. Accessed August 17, 2015.
38. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
39. Rosenbaum PR, Rubin, DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat. 1985;39:33-38.
40. Šidák Z. Rectangular confidence regions for the means of multivariate normal distributions. J Am Stat Assoc. 1967:626-633.
41. Strbian D, Michel P, Seiffge DJ, Saver JL, Numminen H, Meretoja A, Murao K, Weder B, Forss N, Parkkila AK, Eskandari A, Cordonnier C, Davis SM, Engelter ST, Tatlisumak T. Symptomatic intracranial hemorrhage after stroke thrombolysis: comparison of prediction scores. Stroke. 2014;45:752-758. doi: 10.1161/STROKEAHA.113.003806.
42. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, Von Kummer R, Wahlgren N, Toni D; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329. doi: 10.1056/NEJMoa0804656.
43. Ploen R, Sun L, Zhou W, Heitmeier S, Zorn M, Jenetzky E, Veltkamp R. Rivaroxaban does not increase hemorrhage after thrombolysis in experimental ischemic stroke. J Cereb Blood Flow Metab. 2014;34:495-501. doi: 10.1038/jcbfm.2013.226.
44. Kono S, Yamashita T, Deguchi K, Omote Y, Yunoki T, Sato K, Kurata T, Hishikawa N, Abe K. Rivaroxaban and apixaban reduce hemorrhagic transformation after thrombolysis by protection of neurovascular unit in rat. Stroke. 2014;45:2404-2410. doi: 10.1161/STROKEAHA.114.005316.
45. Pfeilschifter W, Bohmann F, Baumgarten P, Mittelbronn M, Pfeilschifter J, Lindhoff-Last E, Steinmetz H, Foerch C. Thrombolysis with recombinant tissue plasminogen activator under dabigatran anticoagulation in experimental stroke. Ann Neurol. 2012;71:624-633. doi: 10.1002/ana.23558.
46. Sun L, Zhou W, Ploen R, Zorn M, Veltkamp R. Anticoagulation with dabigatran does not increase secondary intracerebral haemorrhage after thrombolysis in experimental cerebral ischaemia. Thromb Haemost. 2013;110:153-161. doi: 10.1160/TH12-12-0942.
47. Rybinnik I, Mullen MT, Messe S, Kasner SE, Cucchiara B. Treatment of acute stroke in patients on dabigatran: a survey of US stroke specialists. J Stroke. Cerebrovasc Dis. 2013;22:1312-1316. doi: 10.1016/j. jstrokecerebrovasdis.2012.12.005.
48. Harenberg J, Kraemer R. Measurement of the new anticoagulants. Thromb Res. 2012;129 Suppl 1:S106-S113. doi: 10.1016/S0049-3848 (12) 70028-2.
49. Kate M, Szkotak A, Witt A, Shuaib A, Butcher K. Proposed approach to thrombolysis in dabigatran-treated patients presenting with ischemic stroke. J Stroke. Cerebrovasc Dis. 2014;23:1351-1355. doi: 10.1016/j. jstrokecerebrovasdis.2013.11.013.
50. De Marchis GM, Jung S, Colucci G, Meier N, Fischer U, Weck A, Mono ML, Galimanis A, Mattle HP, Schroth G, Gralla J, Arnold M, Brekenfeld C. Intracranial hemorrhage, outcome, and mortality after intra-arterial therapy for acute ischemic stroke in patients under oral anticoagulants. Stroke. 2011;42:3061-3066. doi: 10.1161/STROKEAHA.111.615476.
51. Nogueira RG, Smith WS; MERCI and Multi MERCI Writing Committee. Safety and efficacy of endovascular thrombectomy in patients with abnormal hemostasis: pooled analysis of the MERCI and multi MERCI trials. Stroke. 2009;40:516-522. doi: 10.1161/STROKEAHA.108.525089.